Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. (Q38056554)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Massimo Broggini

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

A Fasolo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

C Sessa

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

30 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

14-20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110808%20AND%20SRC:MED&resulttype=core&format=json

Drug development of MET inhibitors: targeting oncogene addiction and expedience

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

MET signalling: principles and functions in development, organ regeneration and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Development of c-MET pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Targeting the HGF/c-Met axis: state of play.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Targeting the MET oncogene in cancer and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

The MET receptor tyrosine kinase in invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Ron kinase transphosphorylation sustains MET oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS520